You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
45 search results for: patient case
expert video
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Pulmonology
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
Join Klaus Rabe, MD, PhD, Stephanie Christenson, MD, PhD, and Dave Singh, MD, FERS, FBPhS as they discuss the relationship between clinical presentation and disease pathology, unravel the diverse inflammatory pathways driving COPD's heterogeneity, and review the evolving clinical landscape.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.